AstraZeneca Reports P-III Trial (AEGEAN) Results of Imfinzi (durvalumab) for Non-Small Cell Lung Cancer
Shots:
- The P-III trial (AEGEAN) evaluating Imfinzi (1500mg) + CT vs PBO + CT in 802 patients with resectable Stage IIA-IIIB NSCLC, irrespective of PD-L+1 expression at 264 centers in 25+ countries incl. in the US, Canada, EU, South America & Asia
- The results showed that patients treated with Imfinzi + CT & as adjuvant monotx. achieved an improvement in EFS, results from the final pCR & mPR analyses were consistent with prior positive results, was well tolerated with no new safety concerns in the neoadjuvant & adjuvant settings
- The combination therapy was consistent with the known profile. Imfinzi was approved in the US, EU, Japan, China & many other countries globally for extensive-stage SCLC, based on P-III trial (CASPIAN) results
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receives EU Approval for Advanced Liver and Non-Small Cell Lung Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
